Calidi Biotherapeutics (CLDI) updates public presentation for investors

Rhea-AI Filing Summary

Calidi Biotherapeutics, Inc. filed a current report to note that it has made an updated corporate presentation available on its website. The presentation is furnished as Exhibit 99.1, giving investors structured information about the company in slide format. The company states that this information is provided under Regulation FD, is considered “furnished” rather than “filed,” and is therefore not subject to certain liability provisions of the Exchange Act. Calidi also clarifies that the presentation will not be automatically incorporated into any of its Securities Act or Exchange Act filings unless specifically referenced in the future.

false 0001855485 0001855485 2025-08-29 2025-08-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 29, 2025

CALIDI BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40789		86-2967193
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

4475 Executive Drive, Suite 200, San Diego, California		92121
(Address of principal executive offices)		(Zip Code)

(858) 794-9600

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common stock, par value $0.0001 per share		CLDI		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On August 29, 2025, Calidi Biotherapeutics, Inc. (the “Company”) made available on its website an updated presentation in relation to the Company. Furnished as Exhibit 99.1 hereto and incorporated by reference herein is the presentation.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information in this Item 7.01 disclosure, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. In addition, the information in this Item 7.01 disclosure, including Exhibits 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit		Exhibit Description
99.1		Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CALIDI BIOTHERAPEUTICS, INC.
Dated: August 29, 2025
	By:	/s/ Andrew Jackson
	Name:	Andrew Jackson
	Title:	Chief Financial Officer

FAQ

What did Calidi Biotherapeutics (CLDI) disclose in this 8-K?

Calidi Biotherapeutics disclosed that it has made an updated corporate presentation available on its website, which is included in the filing as Exhibit 99.1.

What is included as Exhibit 99.1 in Calidi Biotherapeutics' 8-K?

Exhibit 99.1 is a presentation relating to Calidi Biotherapeutics, intended to provide additional information about the company to investors.

Is the Calidi Biotherapeutics (CLDI) presentation considered filed with the SEC?

No. The company states that the information in Item 7.01, including Exhibit 99.1, is being furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

Will the Calidi Biotherapeutics presentation be incorporated into other SEC filings?

The company explains that the Item 7.01 information, including Exhibit 99.1, will not be incorporated by reference into its Securities Act or Exchange Act filings unless specifically stated.

Under which item of Form 8-K did Calidi Biotherapeutics provide this information?

The updated presentation is provided under Item 7.01, Regulation FD Disclosure, which focuses on fair and broad dissemination of company information.

Who signed the Calidi Biotherapeutics 8-K related to the presentation?

The report was signed on behalf of Calidi Biotherapeutics by Andrew Jackson, Chief Financial Officer.